Arcline Investment Management announces acquisition of majority interest Akron Biotechnology.
Global Banking News-September 11, 2019-Arcline Investment Management announces acquisition of majority interest Akron Biotechnology
(C)2019 ENPublishing - http://www.enpublishing.co.uk
Private equity firm Arcline Investment Management (Arcline), which has USD1.5bn of capital under management, revealed on Wednesday that it has acquired a majority interest in Akron Biotechnology LLC (Akron), a supplier of cGMP-compliant products and services for the production of advanced therapy medicinal products such as cell therapies, gene therapies and engineered tissues.
Arcline stated that Claudia Zylberberg, PhD, Akron's founder and CEO and a member of its board of directors, will continue to lead Akron.
Akron was founded in 2006 and offers cGMP products such as cytokines and growth factors, cryopreservation solutions and cell culture media supplements. It also offers services that include recombinant protein development, fill & finish, scaffold fabrication and media development.
Arcline added that it plans to work with the Akron team to make targeted complementary acquisitions within the cell and gene therapy manufacturing tools, ancillary materials and services continuum. This will include downstream technologies such as testing, quality control, purification, and fill & finish in addition to product categories such as disposables, human primary cells, viral/non-viral transduction, plasmid DNA and clinical grade tools for CRISPR gene editing.
((Distributed via M2 Communications - http://www.m2.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||Global Banking News (GBN)|
|Date:||Sep 11, 2019|
|Previous Article:||Soligenix announces appointment of Jonathan Guarino as SVP and CFO.|
|Next Article:||Northern Oil and Gas, Inc names Nicholas O'Grady as president.|